Eprosartan
Title: Eprosartan
CAS Registry Number: 133040-01-4
CAS Name: (aE)-a-[[2-Butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene]-2-thiophenepropanoic acid
Additional Names: (E)-3-[2-butyl-1-[(4-carboxyphenyl)methyl]-imidazol-5-yl]-2-(2-thienylmethyl)-2-propenoic acid
Manufacturers' Codes: SKF-108566
Molecular Formula: C23H24N2O4S
Molecular Weight: 424.51
Percent Composition: C 65.07%, H 5.70%, N 6.60%, O 15.08%, S 7.55%
Literature References: Prototype of the imidazoleacrylic acid angiotensin II receptor antagonists. Prepn: J. A. Finkelstein et al., EP 403159 (1990 to SmithKline Beckman); eidem, US 5185351 (1993 to SmithKline Beecham); J. Weinstock et al., J. Med. Chem. 34, 1514 (1991); R. M. Keenan et al., ibid. 36, 1880 (1993). Pharmacology: R. M. Edwards et al., J. Pharmacol. Exp. Ther. 260, 175 (1992). Receptor binding study: H. T. Schambye et al., Mol. Pharmacol. 47, 425 (1995). Clinical pharmacokinetics: D. Tenero et al., Biopharm. Drug Dispos. 19, 351 (1998). Clinical trial in hypertension: W. J. Elliott et al., J. Hum. Hypertens. 13, 413 (1999). Review of clinical experience: L. Ruilope, B. Jäger, Expert Opin. Pharmacother. 4, 107-114 (2003).
Properties: Crystals from methanol, mp 260-261°.
Melting point: mp 260-261°
 
Derivative Type: Monomethanesulfonate
CAS Registry Number: 144143-96-4
Additional Names: Eprosartan mesylate
Manufacturers' Codes: SKF-108566J
Trademarks: Teveten (Solvay)
Molecular Formula: C23H24N2O4S.CH3SO3H
Molecular Weight: 520.62
Percent Composition: C 55.37%, H 5.42%, N 5.38%, O 21.51%, S 12.32%
Properties: White to off-white crystalline powder, mp 248-250°. Insol in water. Freely sol in ethanol.
Melting point: mp 248-250°
 
Therap-Cat: Antihypertensive.
Keywords: Angiotensin II Receptor Antagonist; Antihypertensive; Imidazoleacrylic Acid Derivatives.

Others monographs:
AlaceprilAcemannanPodophyllic AcidsNitric Acid
AzosemideTetrasilaneCyproheptadineBupivacaine
DiethylpropionMagnesium Benzoate2-Furanacrylic AcidZinc Pyrophosphate
AlloxantinGlutaronitrileThujoneFlavoxanthin
©2016 DrugLead US FDA&EMEA